Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Aug;72(2):344–350. doi: 10.1038/bjc.1995.336

Mechanisms for optimising photodynamic therapy: second-generation photosensitisers in combination with mitomycin C.

I P van Geel 1, H Oppelaar 1, Y G Oussoren 1, J J Schuitmaker 1, F A Stewart 1
PMCID: PMC2034009  PMID: 7640216

Abstract

Mechanisms for improving photodynamic therapy (PDT) were investigated in the murine RIF1 tumour using meso-tetrahydroxyphenylchlorin (m-THPC) or bacteriochlorin a (BCA) as photosensitisers and comparing these results with Photofrin-mediated PDT. The 86Rb extraction technique was used to measure changes in perfusion at various times after interstitial PDT. Non-curative combinations of light doses with m-THPC and BCA PDT markedly decreased vascular perfusion. This decrease was more pronounced for both new photosensitisers than for Photofrin. Comparison of tumour perfusion after PDT with tumour response revealed an inverse correlation for all three photosensitisers, but the relationship was less clear for m-THPC and BCA. In vivo/in vitro experiments were performed after Photofrin or m-THPC PDT in order to assess direct tumour kill (immediate plating) vs indirect vascular effects (delayed plating). For both photosensitisers, there was little direct cell killing but clonogenic survival decreased as the interval between treatment and excision increased. When m-THPC PDT was combined with mitomycin C (MMC), light doses could be decreased by a factor of 2 for equal tumour effects. Lower light and m-THPC doses could be used compared with Photofrin PDT in combination with MMC. BCA PDT with MMC did not result in a greater tumour response compared with BCA PDT alone. Reduction in both light and photosensitiser does for effective PDT regimes in combination with MMC offers substantial clinical advantages, since both treatment time and skin photosensitisation will be reduced.

Full text

PDF
344

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baas P., Michielsen C., Oppelaar H., van Zandwijk N., Stewart F. A. Enhancement of interstitial photodynamic therapy by mitomycin C and EO9 in a mouse tumour model. Int J Cancer. 1994 Mar 15;56(6):880–885. doi: 10.1002/ijc.2910560621. [DOI] [PubMed] [Google Scholar]
  2. Baas P., Oppelaar H., Stavenuiter M., van Zandwijk N., Stewart F. A. Interaction of the bioreductive drug SR 4233 and photodynamic therapy using photofrin in a mouse tumor model. Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):665–670. doi: 10.1016/0360-3016(93)90394-b. [DOI] [PubMed] [Google Scholar]
  3. Bremner J. C., Adams G. E., Pearson J. K., Sansom J. M., Stratford I. J., Bedwell J., Bown S. G., MacRobert A. J., Phillips D. Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145. Br J Cancer. 1992 Dec;66(6):1070–1076. doi: 10.1038/bjc.1992.412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bugelski P. J., Porter C. W., Dougherty T. J. Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. Cancer Res. 1981 Nov;41(11 Pt 1):4606–4612. [PubMed] [Google Scholar]
  5. CASTELLANI A., PACE G. P., CONCIOLI M. Photodynamic effect of haematoporphyrin on blood microcirculation. J Pathol Bacteriol. 1963 Jul;86:99–102. doi: 10.1002/path.1700860111. [DOI] [PubMed] [Google Scholar]
  6. Dougherty T. J., Cooper M. T., Mang T. S. Cutaneous phototoxic occurrences in patients receiving Photofrin. Lasers Surg Med. 1990;10(5):485–488. doi: 10.1002/lsm.1900100514. [DOI] [PubMed] [Google Scholar]
  7. Gonzalez S., Arnfield M. R., Meeker B. E., Tulip J., Lakey W. H., Chapman J. D., McPhee M. S. Treatment of Dunning R3327-AT rat prostate tumors with photodynamic therapy in combination with misonidazole. Cancer Res. 1986 Jun;46(6):2858–2862. [PubMed] [Google Scholar]
  8. Henderson B. W., Waldow S. M., Mang T. S., Potter W. R., Malone P. B., Dougherty T. J. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res. 1985 Feb;45(2):572–576. [PubMed] [Google Scholar]
  9. Moore R. B., Chapman J. D., Mercer J. R., Mannan R. H., Wiebe L. I., McEwan A. J., McPhee M. S. Measurement of PDT-induced hypoxia in Dunning prostate tumors by iodine-123-iodoazomycin arabinoside. J Nucl Med. 1993 Mar;34(3):405–411. [PubMed] [Google Scholar]
  10. Ris H. B., Altermatt H. J., Inderbitzi R., Hess R., Nachbur B., Stewart J. C., Wang Q., Lim C. K., Bonnett R., Berenbaum M. C. Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br J Cancer. 1991 Dec;64(6):1116–1120. doi: 10.1038/bjc.1991.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ris H. B., Altermatt H. J., Nachbur B., Stewart J. C., Wang Q., Lim C. K., Bonnett R., Althaus U. Effect of drug-light interval on photodynamic therapy with meta-tetrahydroxyphenylchlorin in malignant mesothelioma. Int J Cancer. 1993 Jan 2;53(1):141–146. doi: 10.1002/ijc.2910530126. [DOI] [PubMed] [Google Scholar]
  12. Schuitmaker J. J., van Best J. A., van Delft J. L., Dubbelman T. M., Oosterhuis J. A., de Wolff-Rouendaal D. Bacteriochlorin a, a new photosensitizer in photodynamic therapy. In vivo results. Invest Ophthalmol Vis Sci. 1990 Aug;31(8):1444–1450. [PubMed] [Google Scholar]
  13. Star W. M., Marijnissen H. P., van den Berg-Blok A. E., Versteeg J. A., Franken K. A., Reinhold H. S. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res. 1986 May;46(5):2532–2540. [PubMed] [Google Scholar]
  14. Twentyman P. R. An artefact in clonogenic assays of bleomycin cytotoxicity. Br J Cancer. 1977 Nov;36(5):642–644. doi: 10.1038/bjc.1977.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Twentyman P. R., Brown J. M., Gray J. W., Franko A. J., Scoles M. A., Kallman R. F. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst. 1980 Mar;64(3):595–604. [PubMed] [Google Scholar]
  16. van Geel I. P., Oppelaar H., Oussoren Y. G., Stewart F. A. Changes in perfusion of mouse tumours after photodynamic therapy. Int J Cancer. 1994 Jan 15;56(2):224–228. doi: 10.1002/ijc.2910560214. [DOI] [PubMed] [Google Scholar]
  17. van Geel I. P., Oppelaar H., Oussoren Y. G., van der Valk M. A., Stewart F. A. Photosensitizing efficacy of MTHPC-PDT compared to photofrin-PDT in the RIF1 mouse tumour and normal skin. Int J Cancer. 1995 Jan 27;60(3):388–394. doi: 10.1002/ijc.2910600320. [DOI] [PubMed] [Google Scholar]
  18. van Leengoed H. L., Schuitmaker J. J., van der Veen N., Dubbelman T. M., Star W. M. Fluorescence and photodynamic effects of bacteriochlorin a observed in vivo in 'sandwich' observation chambers. Br J Cancer. 1993 May;67(5):898–903. doi: 10.1038/bjc.1993.168. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES